EURETINA 2024: Alexandra Miere, MD, PhD, sees oculomics rising to the top

News
Video

Editorial advisory board member Alexandra Miere, MD, PhD, says oculomics is the next big thing in eye care

At this year's EURETINA congress, Alexandra Miere, MD, PhD, an editorial advisory board member for Ophthalmology Times Europe, stopped by the booth to talk about her conference experience. In this video, she discusses the rise of oculomics, her presenation on BLIP (Benign Lobular INL Proliferation), artificial intelligence (AI) applications in inherited retinal diseases, and more.

Editor's note: The below transcript has been lightly edited for clarity.

Alexandra Miere, MD, PhD: Hi, I'm Alexandra Miere. I am an Associate Professor of Ophthalmology at the University Paris Est Créteil. I'm a retina specialist with a focus on retinal imaging and AI applications.

So, at EURETINA this year, I had the pleasure of talking about BLIP. BLIP is a new entity that stands for Benign Lobular Inner Nuclear Layer Proliferation. It's a benign tumour that has a very unique aspect in OCT and FAS.

And then, I talked about the OCT and angiography changes after hemodialysis in end stage kidney disease. So as you all know, oculomics is a field that is getting more and more traction. There is more and more emphasis on what the eye can tell us of systemic disease. And this small study that we formed in [University Paris Est Créteil] last year is part of this new trend in oculomics, I think.

I spoke about AI applications in inherited retinal diseases. Inherited retinal diseases are very rare diseases that are quite difficult to diagnose. And using AI, most particularly deep learning algorithms, we are able, using fundus autofluorescence, for example, or OCT, to detect very nicely the more frequent retinal diseases. This will probably change the paradigm, get the patients to have a referral more rapidly, and when we will have available treatment, we will also allow more rapid access to those new treatments.

This year, there were many, many sessions. I particularly enjoyed the sessions on AI that I’ve already seen. The one on oculomics was very interesting, but it's a topic that I'm particularly interested in, I think. And then there were some very interesting sessions on geographic atrophy and on the OCT and OCT-A applications in various retinal diseases yesterday. There were many, many presentations I really enjoyed.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.